

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA

Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies [ID2697]

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

No potential equality issues have been identified during the scoping process.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Not applicable.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No changes have been made.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No additional stakeholders have been identified.

Approved by Associate Director (name):Janet Robertson.....

Date: 23 June 2020